Chondrosarcoma Clinical Trial Pipeline: Emerging Therapies and Key Developments Shaping the Treatment Landscape | DelveInsight

DelveInsight released a comprehensive report on the chondrosarcoma clinical trial pipeline, highlighting 5+ emerging therapies in development by key players. Notable drugs include Ozekibart (INBRX-109) which received FDA acceptance for filing with a PDUFA goal date of April 2027, Ivosidenib in Phase III trials, and RBT-102 in preclinical stages. The pipeline focuses on novel mechanisms including DR5 agonism and IDH1 inhibition to address this rare, high-unmet-need oncology market.